An interventional study of carotid-femoral pulse-wave velocity in Covid19, Arterial Stiffness and Endothelial Dysfunction, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-22.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Assistance Publique - Hôpitaux de Paris.
Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, this one is the 17th largest by planned enrollment of the 59 interventional ones that give a count, is one of 68 that started in 2020, is one of 33 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 51st registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →9 of the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–74
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 14
First in 2020; this study’s year is marked. 68 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 150 across the 59 interventional studies, 489 across the 56 observational. Of the 60 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in COVID-19 by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the presence of early vascular aging 6 months and 12 months after COVID-19 infection.
After being informed about the study and potential risks, all eligible patients giving written informed consent will undergo a comprehensive non-invasive assessment of vascular and cardiac function 6 months and 12 months after COVID-19 infection. Cardiovascular events and mortality will be collected 2, 5 and 10 years after inclusion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
Diagnostic Test: carotid-femoral pulse-wave velocity
Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
Diagnostic Test: carotid-femoral pulse-wave velocity
Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
Diagnostic Test: carotid-femoral pulse-wave velocity
4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
Diagnostic Test: carotid-femoral pulse-wave velocity
early vascular aging tests
Also known as: arterial distensibility, wave separation/intensity analysis, flow-mediated dilation, cardiac diastolic dysfunction, myocardial stiffness, central blood pressure
PWV
carotid-femoral pulse wave velocity measured by application tonometry
Time frame: 6 months after COVID19 infection
PWV
carotid-femoral pulse wave velocity measured by application tonometry
Time frame: 12 months after COVID19 infection
PWV change
carotid-femoral pulse wave velocity measured by application tonometry
Time frame: difference between PWV at 12 and 6 months after COVID19 infection
arterial distensibility
carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Time frame: 6 months after COVID19 infection
arterial distensibility
carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Time frame: 12 months after COVID19 infection
arterial distensibility change
carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Time frame: difference between arterial distensibility at 12 and 6 months after COVID19 infection
brachial artery FMD
brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Time frame: 6 months after COVID19 infection
brachial artery FMD
brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Time frame: 12 months after COVID19 infection
brachial artery FMD change
brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Time frame: difference between FMD at 12 and 6 months after COVID19 infection
central blood pressure
central blood pressure obtained non-invasively by application tonometry and validated transfer function
Time frame: 6 months after COVID19 infection
central blood pressure
central blood pressure obtained non-invasively by application tonometry and validated transfer function
Time frame: 12 months after COVID19 infection
central blood pressure (BP) change
central blood pressure obtained non-invasively by application tonometry and validated transfer function
Time frame: difference between central BP at 12 and 6 months after COVID19 infection
wave separation/wave intensity analysis (WSA/WIA)
peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Time frame: 6 months after COVID19 infection
wave separation/wave intensity analysis (WSA/WIA)
peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Time frame: 12 months after COVID19 infection
WSA/WIA change
peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Time frame: difference between WSA/WIA at 12 and 6 months after COVID19 infection
cardiac diastolic dysfunction
E/e' at rest and after low-level exercise
Time frame: 6 months after COVID19 infection
cardiac diastolic dysfunction
E/e' at rest and after low-level exercise
Time frame: 12 months after COVID19 infection
cardiac diastolic dysfunction change
E/e' at rest and after low-level exercise
Time frame: difference between cardiac diastolic dysfunction at 12 and 6 months after COVID19 infection
myocardial stiffness
cardioelastography by ultrafast ultrasound
Time frame: 6 months after COVID19 infection
myocardial stiffness
cardioelastography by ultrafast ultrasound
Time frame: 12 months after COVID19 infection
myocardial stiffness change
cardioelastography by ultrafast ultrasound
Time frame: difference between myocardial stiffness at 12 and 6 months after COVID19 infection
carotid femoral and hearth carotid change
Mesure by laser doppler vibrometry
Time frame: 6 months after COVID19 infection
total mortality
individual data will be meta-analyzed with sister studies running in parallel worldwide
Time frame: 2 years
total mortality
individual data will be meta-analyzed with sister studies running in parallel worldwide
Time frame: 5 years
total mortality
individual data will be meta-analyzed with sister studies running in parallel worldwide
Time frame: 10 years
CV events
fatal+non-fatal
Time frame: 2 years
CV events
fatal+non-fatal
Time frame: 5 years
CV events
fatal+non-fatal
Time frame: 10 years
Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
Supporting information: Study protocol, Informed consent form
Time frame: One year after the last publication
Access criteria: Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. The founder could be involved in the decision. Teams wishing obtain IPD must meet the sponsor and PI team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.
Started Sep 2020 (actual). Primary completion is estimated for Mar 2023, 30 months after the start.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 30 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →